Ozempic tied to improved quality of life in type 2 diabetes, CKD

Дата публикации: 12-06-2026 14:32:00

Compared with placebo, semaglutide was associated with improved quality of life outcomes for patients with type 2 diabetes and chronic kidney disease.Study data were presented at the European Renal Association Congress in Glasgow, Scotland.In the FLOW trial, semaglutide (Ozempic, Novo Nordisk) demonstrated efficacy in reducing risks for major adverse kidney events and all-cause mortality compared with placebo for patients with type 2 diabetes and CKD, according to Johannes F. E. Mann, MD, professor of medicine at the Friedrich Alexander University in Germany, and colleagues. Building off

Классификация: Пресс-релизы

Схожие новости

#	Наименование новости	Тональность	Информативность
1	Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity	0	0
2	Can Ozempic lessen the risk of broken bones?	0	0
3	GLP-1s linked to elevated rates of hypotensive events	0	0
4	Sleep Apnea May Amplify GLP-1 Survival Benefits in Type 2 Diabetes	0	0
5	TRACK trial: Rivaroxaban fails to lower CV risks in advanced CKD	0	0
6	Expanded hemodialysis noninferior to online hemodiafiltration	0	0
7	Diabetes linked to higher mortality risk after organ transplantation	0	0
8	At-home UACR test improves testing, follow-up rates	0	0
9	Combined creatinine-cystatin C may be comparable to measured GFR	0	0
10	This GLP-1 drug may be best for weight loss	0	0

• Тональность 0
• Информативность 0
• www.healio.com